Publications by the researcher in collaboration with Concepción Blanco Carrera (20)

2024

  1. ERRATUM: Pegvisomant and pasireotide in PRL and GH co-secreting vs GH-secreting Pit-NETs

    Endocrine-related cancer

  2. Effectiveness of combined first-line medical treatment in acromegaly with prolactin cosecretion

    European Journal of Endocrinology, Vol. 190, Núm. 6, pp. 458-466

  3. Glucose metabolism outcomes after pituitary surgery in patients with acromegaly

    Pituitary, Vol. 27, Núm. 5, pp. 497-506

  4. Integrative clinical, hormonal, and molecular data associate with invasiveness in acromegaly: REMAH study

    European Journal of Endocrinology, Vol. 190, Núm. 6, pp. 421-433

  5. Pegvisomant and pasireotide in PRL and GH co-secreting vs GH-secreting Pit-NETs

    Endocrine-Related Cancer, Vol. 31, Núm. 7

2023

  1. Revisiting the usefulness of the short acute octreotide test to predict treatment outcomes in acromegaly

    Frontiers in Endocrinology, Vol. 14

2022

  1. Acromegaly disease activity according to ACRODAT®, a cross-sectional study in Spain: ACROVAL study

    Endocrine, Vol. 75, Núm. 2, pp. 525-536

2021

  1. Craniopharyngioma in the Elderly: A Multicenter and Nationwide Study in Spain

    Neuroendocrinology, Vol. 111, Núm. 10, pp. 925-936

  2. Molecular determinants of enhanced response to somatostatin receptor ligands after debulking in large GH-producing adenomas

    Clinical Endocrinology, Vol. 94, Núm. 5, pp. 811-819

2020

  1. Lat-1 and glut-1 carrier expression and its prognostic value in gastroenteropancreatic neuroendocrine tumors

    Cancers, Vol. 12, Núm. 10, pp. 1-18

2019

  1. ACROSTART: A retrospective study of the time to achieve hormonal control with lanreotide Autogel treatment in Spanish patients with acromegaly

    Endocrinologia, Diabetes y Nutricion, Vol. 66, Núm. 5, pp. 320-329

2018

  1. Analysis of expression of the PD-1/PD-L1 immune checkpoint system and its prognostic impact in gastroenteropancreatic neuroendocrine tumors

    Scientific Reports, Vol. 8, Núm. 1

2017

  1. Prevalence of acromegaly in patients with symptoms of sleep apnea

    PLoS ONE, Vol. 12, Núm. 9

2016

  1. Use of lanreotide in combination with cabergoline or pegvisomant in patients with acromegaly in the clinical practice: The ACROCOMB study

    Endocrinología y nutrición: órgano de la Sociedad Española de Endocrinología y Nutrición, Vol. 63, Núm. 8, pp. 397-408

2015

  1. Analysis of IGF(CA)19 and IGFBP3-202A/C gene polymorphisms in patients with acromegaly: Association with clinical presentation and response to treatments

    European Journal of Endocrinology, Vol. 172, Núm. 2, pp. 115-122

2014

  1. Escape and lipodystrophy in acromegaly during pegvisomant therapy, a retrospective multicentre Spanish study

    Clinical Endocrinology, Vol. 81, Núm. 6, pp. 883-890

2013

  1. Changes in acromegaly treatment over four decades in Spain: Analysis of the Spanish Acromegaly Registry (REA)

    Pituitary, Vol. 16, Núm. 1, pp. 115-121

2012

  1. El año 2011 en Neuroendocrinología

    Endocrinología y nutrición: órgano de la Sociedad Española de Endocrinología y Nutrición, Vol. 59, Núm. 5, pp. 311-325

2010

  1. Tumores neuroendocrinos

    Endocrinología y nutrición: órgano de la Sociedad Española de Endocrinología y Nutrición, Vol. 57, Núm. 1, pp. 24-29

2004

  1. Epidemiology, clinical characteristics, outcome, morbidity and mortality in acromegaly based on the Spanish Acromegaly Registry (Registro Español de Acromegalia, REA)

    European Journal of Endocrinology, Vol. 151, Núm. 4, pp. 439-446